Skip to main content
. 2019 Jan 4;8:658. doi: 10.3389/fonc.2018.00658

Figure 1.

Figure 1

(A) PCA of Normalized mutation rate (nMR) patterns based on all mutations for 5,956 samples representing 15 primary human tumor localizations, reflected by the color key. Each point on the plot represents one tumor sample. Abbreviations for the cancer types: BRCA, breast invasive carcinoma; LGG, brain lower grade glioma; GBM, glioblastoma multiforme; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; LAML, acute myeloid leukemia; KIRP, kidney renal papillary cell carcinoma; KIRC, kidney renal clear cell carcinoma; COADREAD, colorectal cancer; LICA, liver cancer; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; BLCA, bladder urothelial carcinoma. (B) PCA of Pathway instability (PI) patterns based on all mutations for the same samples. (C) PCA of Normalized mutation rate (nMR) patterns based on the truncating mutations for 5,297 tumor samples. (D) PCA of Pathway instability (PI) patterns based on the truncating mutations for 5,297 tumor samples.